Tarsus Pharmaceuticals annual total assets
2019
2020
2021
2022
2023
2024
2025
Tarsus Pharmaceuticals Total Assets Growth & History (TARS)
Tarsus Pharmaceuticals's total assets was $562.2M for fiscal 2025.
View full Tarsus Pharmaceuticals company overviewTarsus Pharmaceuticals annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $562.2M | $185.2M | +49.12% |
| 2024 | 2024-12-31 | $377.0M | $111.5M | +42.00% |
| 2023 | 2023-12-31 | $265.5M | $37.6M | +16.51% |
| 2022 | 2022-12-31 | $227.9M | $49.0M | +27.36% |
| 2021 | 2021-12-31 | $178.9M | $6.9M | +4.03% |
| 2020 | 2020-12-31 | $172.0M | $113.7M | +194.90% |
| 2019 | 2019-12-31 | $58.3M | — | — |
Tarsus Pharmaceuticals quarterly total assets
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $611.1M | $116.1M | +23.46% |
| Q1 2026 | 2026-03-31 | $581.1M | $80.4M | +16.05% |
| Q4 2025 | 2025-12-31 | $562.2M | $185.2M | +49.12% |
| Q3 2025 | 2025-09-30 | $534.6M | $158.3M | +42.06% |
| Q2 2025 | 2025-06-30 | $495.0M | $118.2M | +31.35% |
| Q1 2025 | 2025-03-31 | $500.8M | $151.5M | +43.37% |
| Q4 2024 | 2024-12-31 | $377.0M | $111.5M | +42.00% |
| Q3 2024 | 2024-09-30 | $376.3M | $108.0M | +40.24% |
| Q2 2024 | 2024-06-30 | $376.8M | $187.9M | +99.47% |
| Q1 2024 | 2024-03-31 | $349.3M | $138.1M | +65.37% |
| Q4 2023 | 2023-12-31 | $265.5M | $37.6M | +16.51% |
| Q3 2023 | 2023-09-30 | $268.3M | $31.9M | +13.48% |
| Q2 2023 | 2023-06-30 | $188.9M | −$63.9M | −25.27% |
| Q1 2023 | 2023-03-31 | $211.2M | $29.7M | +16.38% |
| Q4 2022 | 2022-12-31 | $227.9M | $49.0M | +27.36% |
| Q3 2022 | 2022-09-30 | $236.5M | $46.1M | +24.19% |
| Q2 2022 | 2022-06-30 | $252.8M | $49.4M | +24.27% |
| Q1 2022 | 2022-03-31 | $181.5M | −$12.5M | −6.43% |
| Q4 2021 | 2021-12-31 | $178.9M | $6.9M | +4.03% |
| Q3 2021 | 2021-09-30 | $190.4M | $98.2M | +106.55% |
| Q2 2021 | 2021-06-30 | $203.4M | — | — |
| Q1 2021 | 2021-03-31 | $194.0M | — | — |
| Q4 2020 | 2020-12-31 | $172.0M | $113.7M | +194.90% |
| Q3 2020 | 2020-09-30 | $92.2M | — | — |
| Q4 2019 | 2019-12-31 | $58.3M | — | — |
Tarsus Pharmaceuticals total assets trends
Over the last five fiscal years, Tarsus Pharmaceuticals's total assets increased from $172.0M to $562.2M, a change of $390.2M. The latest reported quarter, Q2 2026, shows $611.1M.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tarsus Pharmaceuticals source filings ↗